Promising Prospects for Vaxcyte’s VAX-31: Strong Adult Trial Results and Strategic Advancements in Infant Studies Reinforce Buy Rating

In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Vaxcyte, with a price target of $50.00.

Tara Bancroft’s rating is based on the promising prospects of Vaxcyte’s VAX-31 vaccine candidate. The vaccine has shown strong immunogenicity results in adult trials, meeting non-inferiority criteria across all serotypes tested. This success has led to the initiation of a pivotal Phase III study, which is expected to yield significant data by 2026, positioning VAX-31 as a potential leader in the market if competitors fail to develop a similar vaccine.
In addition to the adult trials, Vaxcyte is advancing VAX-31 for infants with an optimized dose in a Phase II study. Although this extends the data timeline to 2027, the company’s strategic adjustments and continued progress in both adult and infant programs reinforce confidence in their potential success. Despite lowering the price target, Bancroft maintains a Buy rating due to the differentiated technology and market opportunity that Vaxcyte’s platform presents.